ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

5,07
-0,23
(-4,34%)
Fermé 08 Février 10:00PM
5,07
0,00
(0,00%)
Après les heures de négociation: 11:16PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
5,07
Prix Achat
4,81
Prix Vente
5,50
Volume échangé
59 426
5,00 Fourchette du Jour 5,5876
2,79 Plage de 52 semaines 11,99
Cap du marché
Clôture Veille
5,30
Ouverture
5,5876
Dernière Transaction
1
@
5
Dernière heure de transaction
Volume financier
US$ 308 034
VWAP
5,1835
Volume moyen (3 m)
108 544
Actions en circulation
10 784 725
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-3,41
Bénéfice par action (BPA)
-1,48
Chiffre d'affairess
-
Bénéfice net
-15,96M

À propos de Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Wilmington, Delaware, USA
Fondé
-
Lantern Pharma Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker LTRN. Le dernier cours de clôture d'Lantern Pharma était de US$5,30. Au cours de la dernière année, les actions de Lantern Pharma ont été négociées dans une fourchette de prix de US$ 2,79 à US$ 11,99.

Lantern Pharma compte actuellement 10 784 725 actions en circulation. La capitalisation boursière d'Lantern Pharma est de US$57,16 million. Lantern Pharma a un ratio cours/bénéfice (ratio PE) de -3.41.

LTRN Dernières nouvelles

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung...

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC...

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

The Phase 1b clinical trial design presented at SNO2024 combines LP-184 (STAR-001) with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma (GBM) patients...

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites...

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for...

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.38998.331018567984.68015.74.6817205.05104518CS
41.2733.42105263163.86.1183.4451657284.98850365CS
121.6146.53179190753.466.1182.791085444.24803795CS
261.2733.42105263163.86.1182.79736514.09040168CS
520.9121.8754.1611.992.791383436.16183445CS
156-1.47-22.47706422026.5411.992.38698675.75231779CS
260-10.09-66.556728232215.1624.842.38766699.28588675CS

LTRN - Frequently Asked Questions (FAQ)

What is the current Lantern Pharma share price?
The current share price of Lantern Pharma is US$ 5,07
How many Lantern Pharma shares are in issue?
Lantern Pharma has 10 784 725 shares in issue
What is the market cap of Lantern Pharma?
The market capitalisation of Lantern Pharma is USD 57,16M
What is the 1 year trading range for Lantern Pharma share price?
Lantern Pharma has traded in the range of US$ 2,79 to US$ 11,99 during the past year
What is the PE ratio of Lantern Pharma?
The price to earnings ratio of Lantern Pharma is -3,41
What is the reporting currency for Lantern Pharma?
Lantern Pharma reports financial results in USD
What is the latest annual profit for Lantern Pharma?
The latest annual profit of Lantern Pharma is USD -15,96M
What is the registered address of Lantern Pharma?
The registered address for Lantern Pharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
Which industry sector does Lantern Pharma operate in?
Lantern Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MGOLMGO Global Inc
US$ 0,4191
(126,54%)
778,37M
CDTConduit Pharmaceuticals Inc
US$ 2,831
(82,65%)
140,23M
GSIWGarden Stage Ltd
US$ 0,79
(78,73%)
215,01M
TOIIWOncology Institute Inc
US$ 0,033
(58,88%)
7,27k
CYTHCyclo Therapeutics Inc
US$ 1,19
(54,55%)
72,25M
FTELFitell Corporation
US$ 2,70
(-57,01%)
2,29M
SGBXSafe and Green Holdings Corporation
US$ 0,6401
(-44,82%)
5,63M
NKLANikola Corporation
US$ 0,4432
(-41,10%)
52,4M
PLRXPliant Therapeutics Inc
US$ 7,785
(-34,85%)
6,21M
LIPOLipella Pharmaceuticals Inc
US$ 3,08
(-33,76%)
2,19M
MGOLMGO Global Inc
US$ 0,4191
(126,54%)
814,49M
RIMEAlgorhythm Holdings Inc
US$ 0,0169
(-20,66%)
272,72M
NVDANVIDIA Corporation
US$ 129,84
(0,90%)
227,84M
GSIWGarden Stage Ltd
US$ 0,79
(78,73%)
219,49M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0537
(14,74%)
211,43M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock